Empagliflozin became the second agent of SGLT2 inhibitors (after dapagliflozin) that produces a significant improvement in cardiovascular death and heart failure hospitalization in patients with severe heart failure, whether diabetic or not. Here, SLC5A2 is linked to heart failure.